Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria

Objectives: A prospective, multicenter, open-label, noninterventional study assessed the efficacy, safety, tolerability, and patient satisfaction with teriflunomide therapy over a 24-month follow-up period under real-world conditions in Austria. Methods: An all-comer population aged ≥18 years was fo...

Full description

Bibliographic Details
Main Authors:	Michael Guger, Michael Matthias Ackerl, Martin Heine, Christiane Hofinger-Renner, Heinrich Karl Spiss, Andrea Taut, Karin Unger, Fritz Leutmezer
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	eNeurologicalSci
Subjects:	Relapsing–remitting multiple sclerosis Disease-modifying treatment Teriflunomide Annualized relapse rate Patient-reported outcomes Patient treatment satisfaction
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405650222000053

Internet

http://www.sciencedirect.com/science/article/pii/S2405650222000053

Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria

Internet

Similar Items